Recon: FTC says PBMs inflated drug prices to generate $7.3B in revenue; GSK to buy IDRx for $1B upfront
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States